| アブストラクト | BACKGROUND: Multimorbidity has been identified as a research priority in recent years, fibrosis (progressive organ scarring) is one mechanism which may underpin multimorbidity. Some studies suggest hypertension could be fibrotic, particularly severe hypertension (uncontrollable with medications), however it is not currently known whether severe hypertension is associated with fibrotic conditions. OBJECTIVE: To investigate whether treatment resistant hypertension is associated with fibrotic conditions. METHODS: We used the Clinical Practice Research Datalink (CPRD) Aurum primary care database to define a cohort of people with hypertension during 2015. We determined the percentage of people who had conditions with fibrotic manifestations and explored differences respective to hypertension control. We applied multivariable logistic regression to analyse associations (p<0.001) between hypertension control and each fibrotic condition respectively. RESULTS: Of 1,340,495 people with hypertension during 2015, 83.50% (n=1,119,333) had managed hypertension either by lifestyle or medication; 16.50% (n=221,162) had treatment resistant hypertension. Fibrotic conditions were more common ((75.40% (95%CI: 75.20-75.60) vs. 68.90% (95%CI: 68.81-70.01)) in people with treatment resistant hypertension compared with those with managed hypertension. We found that treatment resistant hypertension was associated with; cardiomyopathy (ORadj:1.85, 95%CI:1.81-1.90), both type 1 and type 2 diabetes (ORadj:1.49,95%CI:1.44-1.55, ORadj:1.61,95%CI:1.60-1.63, respectively), liver fibrosis (ORadj:1.52, 95%CI: 1.46-1.58), valve fibrosis (ORadj:1.41, 95%CI:1.37-1.44) and urinary fibrosis (ORadj:1.41,95%CI:1.36-1.47). CONCLUSION: The proportion of people with fibrotic conditions was greater in those with treatment resistant hypertension than managed hypertension. The identified associations between treatment resistant hypertension and fibrotic conditions may point to common disease pathways which should be further explored to understand shared mechanisms. |
|---|
| ジャーナル名 | European journal of preventive cardiology |
|---|
| Pubmed追加日 | 2025/2/13 |
|---|
| 投稿者 | Massen, G M; Stone, P W; Jenkins, R G; Allen, R J; Wain, L V; Stewart, I; Tayal, U; Quint, J K |
|---|
| 組織名 | Imperial College London, School of Public Health, 86 wood lane, London SW7 2AZ,;UK.;Imperial College London, National Heart and Lung Institute, London, UK.;University of Leicester, Department of Population Health Sciences, Leicester, UK.;University of Leicester, NIHR Biomedical Research Centre, Leicester, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39943821/ |
|---|
